Expression of standard CD44 in human colorectal carcinoma: Association with prognosis
Article first published online: 30 MAR 2009
© 2009 The Authors. Journal compilation © 2009 Japanese Society of Pathology
Volume 59, Issue 4, pages 241–246, April 2009
How to Cite
Huh, J. W., Kim, H. R., Kim, Y. J., Lee, J. H., Park, Y. S., Cho, S. H. and Joo, J. K. (2009), Expression of standard CD44 in human colorectal carcinoma: Association with prognosis. Pathology International, 59: 241–246. doi: 10.1111/j.1440-1827.2009.02357.x
- Issue published online: 30 MAR 2009
- Article first published online: 30 MAR 2009
- Received 11 November 2008. Accepted for publication 18 December 2008.
- colorectal carcinoma;
The aim of the present study was to evaluate the expression of standard CD44 (CD44s) in colorectal cancer (CRC), its relationship with clinicopathological characteristics, and its potential prognostic significance. CD44s levels were measured on immunohistochemistry in tumors and surrounding normal mucosa from 74 patients with primary colorectal carcinomas. The patients were followed for a median period of 37 months. Expression of CD44s in primary tumor and surrounding normal mucosa tissues was demonstrated in 100% (74/74) and 37.9% (28/74), respectively. The expression of CD44s in tumors was significantly associated with the depth of invasion (P = 0.034) and lymph node involvement (P = 0.031). A significant difference was observed between the overall survival and level of tumor CD44s expression, especially for stage IV carcinoma (P = 0.038). Multivariate analysis indicated that TNM stage (P = 0.020) and tumor CD44s expression (P = 0.008) were independent predictors of overall survival in adenocarcinomas. CD44s overexpression may be an independent unfavorable prognostic factor for overall survival in advanced CRC, especially stage IV disease. Further investigation, however, is necessary to assess the biological roles of CD44 in CRC, and validate their possible value as novel therapeutic targets.